Hemolens Diagnostics and Intercard launch Cardiolens Viewer® pilot

Hemolens Diagnostics Sp. z o.o. together with Intercard Sp. z o.o. – network of medical facilities, are implementing a pilot of the Cardiolens Viewer®, the first module of the Cardiolens® Platform. This tool is dedicated to cardiologists and radiologists for the analysis of coronary computed tomography angiography (CCTA). The solution uses artificial intelligence for automatic segmentation and 3D visualization of coronary vessels, which may allow for faster and more accurate image assessment. The aim of the project is to conduct a pilot of the RUO version of a modern tool, based on major European cardiac and radiological guidelines, designed to support diagnostic decision-making.

Intercard Sp. z o.o. – comprehensive treatment of patients with cardiac conditions

Intercard Sp. z o.o. is a network of medical facilities in Poland, specializing in care for patients with heart diseases since 2005. The company offers services through contracts with the National Health Fund (NFZ) and commercially. Patients receive support at invasive cardiology centers, outpatient clinics, advanced imaging diagnosis centers and a day ward for cardiac rehabilitation, including procedures in invasive cardiology, angiology and electrophysiology. The company is also involved in research activities, running its own Clinical Research Center.

Modern diagnostics in line with international guidelines

The collaboration between Hemolens Diagnostics® and Intercard Sp. z o.o. reflects global changes in medicine, focused on the digitalization and personalization of coronary heart disease diagnostics.

The Cardiolens Viewer® solution addresses the recommendations of leading cardiology organizations, which identify Coronary Computed Tomography Angiography (CCTA) as the first-line diagnostic test:

• The European Society of Cardiology (ESC) granted CCTA a Class I A recommendation in the diagnosis of stable coronary artery disease, according to the latest guidelines from 2024.
• In the United States, in 2021, the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society of Cardiovascular Computed Tomography (SCCT) updated their chest pain guidelines, elevating CCTA to a Class I A recommendation in the evaluation of acute chest pain.
• The Centers for Medicare & Medicaid Services (CMS) more than doubled reimbursement for CCTA – from $175 to $357.13.

In recent years, the Society of Cardiovascular Computed Tomography (SCCT), together with partner organizations in North America and Europe, has published white papers (2024 – 2025) covering technical standards, the use of Artificial Intelligence (AI) and machine learning in CCTA, and standardized reporting frameworks.

All these initiatives support the digital transformation of cardiovascular imaging, with an emphasis on precision, standardization, and minimizing the invasiveness of diagnostics.

Cardiolens Viewer® – rapid analysis of coronary CTA

Cardiolens Viewer® is a cloud-based, AI-powered solution that enables:

• review of coronary CTA scans in the form of an interactive 3D model of the coronary vessels,
• automatic segmentation and visualization of coronary structures,
• analysis of potential arterial narrowing points.

Cardiolens Viewer® is accessible from hospital web browser, facilitating login process for medical professionals. Solution supports as well remote access via protected virtual private network (VPN) as well as can be integrated with hospital IT systems.

Objectives of the pilot implementation at Intercard Sp. z o.o.

As part of the pilot, the Cardiolens Viewer® solution will be implemented at Intercard Sp. z o.o., as a cloud-based architecture that can be accessed across all hospitals’ locations.

Key objectives of the pilot implementation:

• Preclinical validation – assessment of the accuracy and potential usefulness of automatic CCTA analysis in Cardiolens Viewer® within scientific research.
• Integration in pilot studies – testing the feasibility of incorporating Cardiolens Viewer® into standard diagnostic pathways of cardiology and radiology departments as part of research projects.
• Evaluation of potential impact on diagnostic processes – retrospective comparison of analyses generated by Cardiolens Viewer® with results from invasive reference tests (ICA, iFFR) strictly for research and validation purposes.

Value for clinicians

Cardiolens Viewer® offers AI-powered analysis of coronary CTA images, which may assist physicians in the interpretation of complex cardiac anatomies and potentially support clinical decision-making regarding patient management.

The direction of diagnostic development in Europe and worldwide

The pilot project of Hemolens Diagnostics® with Intercard Sp. z o.o. aligns with the global trend of implementing innovative AI-powered tools that comply with current clinical guidelines and the growing expectations of medical regulatory bodies. Such initiatives are also proof that Poland is not only keeping pace with global trends but is becoming an important player in shaping the future of innovation.

Cardiolens Viewer® is intended for research purposes only (Research and Academic Use Only) and is not approved for diagnostic, therapeutic, or other medical use. Use of the software is at the user’s own risk, and the manufacturer shall not be liable for damages resulting from improper use, particularly involving its use to diagnose a particular patient. The software is not authorized for use as a medical device under Regulation (EU) 2017/745 of the European Parliament and of the Council of April 5, 2017, on medical devices and has not been cleared or approved by the FDA.

Sources:

https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Chronic-Coronary-Syndromes

https://scct.org/page/Abstracts_SCCTGlobal2025

https://scct.org/news/685976/U.S.-CMS-agrees-to-double-reimbursement-for-cardiovascular-CT-services.htm